Tyrosine kinase inhibitors (TKI): targets and indications

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Tyrosine kinase inhibitors (TKI): targets and indications. Anaplastic lymphocyte kinase (ALK). Fully referenced neurology checklist.

Targets

  • Anaplastic lymphocyte kinase (ALK)
  • Bruton's tyrosine kinase (BTK)
  • Epidermal growth factor receptor (EGFR)
  • Fibroblast growth factor receptor (FGFR)
  • Human epidermal growth factor receptor 2 (HER2)
  • Mesenchymal-epithelial transition factor (MET)
  • Mitogen-activated protein kinase (MEK)
  • Platelet-derived growth factor receptor (PDGFR)
  • Proto oncogene receptor (KIT)
  • Rearranged during transfection (RET)
  • ROS proto-oncogene 1 (ROS1)
  • SRC proto-oncogene (SRC)
  • Tropomyosin receptor kinase (TRK)
  • Vascular endothelial growth factor receptor (VEGFR)

Indications

Locked: subscribe to see this section.

References

  1. Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018; 17:36.
  2. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020; 13:143.

Related checklists

Loading...